Clinical Trials in Hangzhou, 2026
Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.
About this register
This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.
This page shows the 20 of those studies with a site in Hangzhou that also match the filters currently applied.
How many clinical trials are recruiting in Hangzhou?
19 of the 20 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.
Summary by phase
| Phase | Studies | Recruiting | Share |
|---|---|---|---|
| Phase 1/2 | 11 | 10 | 55% |
| Phase 1 | 8 | 8 | 40% |
| Early Phase 1 | 1 | 1 | 5% |
Most active sponsors
| Lead sponsor | Studies | Recruiting |
|---|---|---|
| FBD Biologics Limited | 2 | 2 |
| Akeso | 1 | 1 |
| Ascentage Pharma Group Inc. | 1 | 1 |
| BeOne Medicines | 1 | 1 |
| BioNTech SE | 1 | 1 |
| Daiichi Sankyo | 1 | 1 |
| Eikon Therapeutics | 1 | 1 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 1 | 0 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 | 1 |
| Latticon Antibody Therapeutics, Inc | 1 | 1 |